Association between IL6 -174G/C and cancer: A meta-analysis of 105,482 individuals

Experimental and Therapeutic Medicine

Volumn 3, Issue 4, 2012, Pages 655-664

  Liu, Reng Yun ^a   Song, Xiaoxue ^a   Chen, Ping ^b   Lei, Zhe ^a   Miao, Jingcheng ^a   Yi, Nengjun ^c   Zhang, Kui ^c   Pasche, Boris ^d   Zhang, Hong Tao ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Cancer risk; Interleukin 6; Meta analysis; Polymorphism

Indexed keywords

INTERLEUKIN 6;

ALLELE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; COLORECTAL CANCER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG CANCER; LYMPHOMA; MELANOMA; META ANALYSIS; MULTIPLE MYELOMA; PROSTATE CANCER; STOMACH CANCER; UTERINE CERVIX CANCER;

EID: 84863061473     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.454     Document Type: Article

References (49)

1. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
2. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell 140: 883-899, 2010.
3. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature 454: 436-444, 2008.
4. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
5. Engels EA, Wu X, Gu J, Dong Q, Liu J and Spitz MR: Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res 67: 6520-6527, 2007.
6. Tindall EA, Severi G, Hoang HN, et al: Comprehensive analysis of the cytokine-rich chromosome 5q31.1 region suggests a role for IL-4 gene variants in prostate cancer risk. Carcinogenesis 31: 1748-1754, 2010.
7. Kishimoto T: Interleukin-6: from basic science to medicine - 40 years in immunology. Annu Rev Immunol 23: 1-21, 2005.
8. Katsumata N, Eguchi K, Fukuda M, et al: Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res 2: 553-559, 1996.
9. Bromberg JF, Wrzeszczynska MH, Devgan G, et al: Stat3 as an oncogene. Cell 98: 295-303, 1999.
10. Grivennikov S, Karin E, Terzic J, et al: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15: 103-113, 2009.
11. Walter M, Liang S, Ghosh S, Hornsby PJ and Li R: Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 28: 2745-2755, 2009.
12. Sullivan NJ, Sasser AK, Axel AE, et al: Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28: 2940-2947, 2009.
13. Fishman D, Faulds G, Jeffery R, et al: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102: 1369-1376, 1998.
14. Belluco C, Olivieri F, Bonafe M, et al: -174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res 9: 2173-2176, 2003.
15. Xu B, Niu XB, Wang ZD, et al: IL-6 -174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls. Mol Biol Rep 38: 2589-2596, 2011.
16. Yu KD, Di GH, Fan L, Chen AX, Yang C and Shao ZM: Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects. Breast Cancer Res Treat 122: 483-488, 2010.
17. Moher D, Liberati A, Tetzlaff J and Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535, 2009.
18. Stroup DF, Berlin JA, Morton SC, et al: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012, 2000.
19. Yu W, Gwinn M, Clyne M, Yesupriya A and Khoury MJ: A navigator for human genome epidemiology. Nat Genet 40: 124-125, 2008.
20. Cochran WG: The combination of estimates from different experiments. Biometrics 10: 101-129, 1954.
21. Dickersin K and Berlin JA: Meta-analysis: state-of-the-science. Epidemiol Rev 14: 154-176, 1992.
22. Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ 327: 557-560, 2003.
23. Lau J, Ioannidis JP and Schmid CH: Summing up evidence: one answer is not always enough. Lancet 351: 123-127, 1998.
24. Patsopoulos NA, Evangelou E and Ioannidis JP: Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 37: 1148-1157, 2008.
25. Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748, 1959.
26. DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials 7: 177-188, 1986.
27. Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634, 1997.
28. Harbord RM, Egger M and Sterne JA: A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25: 3443-3457, 2006.
29. Dossus L, Kaaks R, Canzian F, et al: PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 31: 455-461, 2010.
30. Foster CB, Lehrnbecher T, Samuels S, et al: An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 96: 2562-2567, 2000.
31. Morgan L, Cooper J, Montgomery H, Kitchen N and Humphries SE: The interleukin-6 gene -174G>C and -572G>C promoter polymorphisms are related to cerebral aneurysms. J Neurol Neurosurg Psychiatry 77: 915-917, 2006.
32. Theodoropoulos G, Papaconstantinou I, Felekouras E, et al: Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 12: 5037-5043, 2006.
33. Vairaktaris E, Yapijakis C, Serefoglou Z, et al: Gene expression polymorphisms of interleukins-1 beta, -4, -6, -8, -10, and tumor necrosis factors-alpha, -beta: regression analysis of their effect upon oral squamous cell carcinoma. J Cancer Res Clin Oncol 134: 821-832, 2008.
34. Slattery ML, Wolff RK, Herrick JS, Caan BJ and Potter JD: IL6 genotypes and colon and rectal cancer. Cancer Causes Control 18: 1095-1105, 2007.
35. Hirschhorn JN, Lohmueller K, Byrne E and Hirschhorn K: A comprehensive review of genetic association studies. Genet Med 4: 45-61, 2002.
36. Iliopoulos D, Hirsch HA and Struhl K: An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139: 693-706, 2009.
37. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML and Struhl K: STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39: 493-506, 2010.
38. Okamoto M, Lee C and Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57: 141-146, 1997.
39. Yeh HH, Lai WW, Chen HH, Liu HS and Su WC: Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 25: 4300-4309, 2006.
40. Bromberg J and Wang TC: Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15: 79-80, 2009.
41. Park EJ, Lee JH, Yu GY, et al: Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140: 197-208, 2010.
42. Thompson SG: Why sources of heterogeneity in meta-analysis should be investigated. BMJ 309: 1351-1355, 1994.
43. Sterne JA and Egger M: Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54: 1046-1055, 2001.
44. Robinson GE: Genomics. Beyond nature and nurture. Science 304: 397-399, 2004.
45. Frazer KA, Murray SS, Schork NJ and Topol EJ: Human genetic variation and its contribution to complex traits. Nat Rev Genet 10: 241-251, 2009.
46. Cole SW, Arevalo JM, Takahashi R, et al: Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci USA 107: 5681-5686, 2010.
47. Gu W, Du DY, Huang J, et al: Identification of interleukin-6 promoter polymorphisms in the Chinese Han population and their functional significance. Crit Care Med 36: 1437-1443, 2008.
48. Smith AJ, D'Aiuto F, Palmen J, et al: Association of serum interleukin-6 concentration with a functional IL6 -6331T>C polymorphism. Clin Chem 54: 841-850, 2008.
49. Terry CF, Loukaci V and Green FR: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275: 18138-18144, 2000.